FIVE PRIME THERAPEUTICS INC's ticker is FPRX and the CUSIP is 33830X104. A total of 113 filers reported holding FIVE PRIME THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 469.50 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $0 | -100.0% | 13,118 | +147.9% | 0.00% | – |
| Q4 2020 | $90,000 | – | 5,292 | +2776.1% | 0.00% | – |
| Q3 2020 | $0 | -100.0% | 184 | -99.2% | 0.00% | – |
| Q4 2019 | $106,000 | +562.5% | 23,259 | +437.0% | 0.00% | – |
| Q3 2019 | $16,000 | +433.3% | 4,331 | +612.3% | 0.00% | – |
| Q2 2019 | $3,000 | -96.7% | 608 | -91.2% | 0.00% | – |
| Q1 2019 | $92,000 | +39.4% | 6,888 | -3.2% | 0.00% | – |
| Q4 2018 | $66,000 | -61.6% | 7,119 | -42.5% | 0.00% | -100.0% |
| Q3 2018 | $172,000 | -44.2% | 12,383 | -36.4% | 0.00% | 0.0% |
| Q2 2018 | $308,000 | +15.4% | 19,485 | +25.3% | 0.00% | -91.7% |
| Q1 2018 | $267,000 | +1807.1% | 15,554 | +5263.4% | 0.01% | +1100.0% |
| Q4 2016 | $14,000 | +75.0% | 290 | +81.2% | 0.00% | 0.0% |
| Q3 2016 | $8,000 | -70.4% | 160 | -75.8% | 0.00% | -50.0% |
| Q2 2016 | $27,000 | -69.3% | 660 | -69.1% | 0.00% | -71.4% |
| Q4 2015 | $88,000 | +137.8% | 2,133 | -12.3% | 0.01% | +133.3% |
| Q3 2015 | $37,000 | – | 2,433 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 115,500 | $2,531,000 | 0.89% |
| AWM Investment Company, Inc. | 150,000 | $3,288,000 | 0.64% |
| BB BIOTECH AG | 827,500 | $18,139,000 | 0.51% |
| Virtus ETF Advisers LLC | 17,371 | $381,000 | 0.48% |
| Rock Springs Capital Management LP | 425,000 | $9,316,000 | 0.42% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 450,728 | $9,880,000 | 0.39% |
| Telemetry Investments, L.L.C. | 44,176 | $968,000 | 0.37% |
| RTW INVESTMENTS, LP | 100,377 | $2,200,000 | 0.37% |
| Eventide Asset Management | 315,000 | $6,905,000 | 0.36% |
| ACUTA CAPITAL PARTNERS, LLC | 52,500 | $1,151,000 | 0.22% |